ARTICLES BY MARCUS JOHNSON
Novartis And Roche Fined $251 Million By Italian Government
The Italian government fined drug industry giants Novartis and Roche $251 million dollars for their roles in a collusion plot to prevent Roche’s Avastin cancer drug from being used as a treatment for a disease affecting aging eyes.
Indian Government Claims Counterfeit Drugs Have Invaded The Market
Counterfeit drugs have increasingly shown up in the Indian market, which is a serious problem for the Indian government.
Takeda Pharmaceutical Acknowledges “Inappropriate” Drug Marketing
Takeda Pharmaceutical’s CEO, Tasuchika Hasegawa, has admitted that his company marketed blood pressure drug Blopress in a manner that didn’t align with Japanese law.
Fake FDA Officials Demand Cash From Indian Pharmaceutical Companies
Indian regulators have released a document alerting domestic pharmaceutical companies and foreign pharmaceutical companies to a scam targeted at Indian drug companies.
Endo Pharmaceuticals To Pay Connecticut In Court Resolution
The court case United States ex rel. Ryan v. Endo Pharmaceuticals has reached a settlement. The case started on allegations of wrongdoing on the behalf of Endo Pharmaceuticals.
FDA Wants Changes To Drug Review System
The FDA is looking to make major changes to its non-prescription drug review system—a system which is more than 40 years old.
GlaxoSmithKline Asking For Tougher Regulation On E-Cigarettes
Pharmaceutical giant GlaxoSmithKline is asking the EU for tougher regulation of E-Cigarettes.
Wisconsin Legislation Changes Coverage For Pill Forms Of Cancer Drugs
A new bill in the Wisconsin legislature would change the way that cancer drugs taken orally can be covered by insurance companies.
High Price Of Breast Cancer Drug In New Zealand Could Continue
In New Zealand, the high price of a breast cancer drug is causing concern among the government.
Drug Firm Cadence Bought By Mallinckrodt For $1.3 Billion
Irish drug company Mallinckrodt has come to terms with a purchase price on San Diego based firm Cadence Pharmaceuticals. The price has been reported at $1.3 billion. The deal gives Mallinckrodt control over Cadence’s line of specialty drugs, which were coveted.